Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for UniPharma Co., Ltd. (6621:TWSE), powered by AI.
UniPharma Co., Ltd. is currently trading at $12.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for UniPharma Co., Ltd. on Alpha Lenz.
View UniPharma Co., Ltd.'s valuation metrics on Alpha Lenz.
“UniPharma Co., Ltd.'s ROE is -15.8%. Explore profitability and growth together.”
Ask for details →UniPharma Co., Ltd. is a diversified healthcare company specializing in the distribution of pharmaceutical drugs, medical devices, and diagnostic reagents across Taiwan. Incorporated in 1998 and headquartered in Taipei, UniPharma caters to a broad spectrum of medical professionals by supplying diagnostic tests and therapeutic products in fields such as oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. Its offerings include in-vitro diagnostic tests, various injectable medications—such as morphine analgesics and antidotes for drug overdoses—and specialized equipment for cancer treatment and medical procedures. UniPharma’s clientele encompasses medical centers, regional hospitals, and clinics, reflecting its important role as an intermediary in Taiwan’s healthcare supply chain. The company also engages in drug research and development, clinical trials, and marketing services, contributing to advancements within the nation’s medical technology and specialty drug sectors. Through its comprehensive distribution network and support for innovation, UniPharma occupies a notable position in the regional healthcare market, directly impacting the accessibility and quality of medical supplies and pharmaceuticals available throughout Taiwan.
“UniPharma Co., Ltd.'s ROE is -15.8%. Explore profitability and growth together.”
Ask for details →UniPharma Co., Ltd. (ticker: 6621) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 31 employees.
The current price is 12.15 with a P/E ratio of -x and P/B of -x.
ROE is -15.76% and operating margin is -49.89%. Annual revenue is $88M.